| EGFR |
| LOCUS ID | 1956 | ||||||||||||||||
| GENE_SYMBOL | EGFR | ||||||||||||||||
| GENE NAME | epidermal growth fac | ||||||||||||||||
| SYNONYMNS | ERBB, HER1, mE, ERBB1, PIG61, NISBD2 | ||||||||||||||||
| CHROMOSOME | 7 | ||||||||||||||||
| HOMOLOGENE ID | 74545 |
| microRNAs | NA | NA |
| GENE SUMMARY |
|---|
| The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. Multiple alternatively spliced transcript varian |
| OBSERVATIONS |
|---|
| Complication | Evidence | PMID |
| Nephropathy | 1. EGFR inhibition may be a therapeutic strategy in the treatment of diabetic nephropathy and in limiting salt and water retention, which currently restricts the use of PPA gamma agonists. | 23370527 |
| Cardiovascular | 1. Human epidermal growth factor receptor 2 (HER2) status, hypertension, and coronary artery disease were significant predictors for both heart failure groups (p< 0.001). Type II diabetes was a risk factor for the late-onset AIHF group (p<0.001).HER2 status and cardiovascular risk factors increased the risk of heart failure among doxorubicin users. Patients with type II diabetes were at increased risk of late-onset anthracycline-induced heart failure (AIHF). | 25342090 |
| Insulin resistance and inflammation | 1. PD153035 (EGFR tyrosine kinase inhibitor) treatment for 1 day decreased the protein expression of inducible nitric oxide synthase, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-6 in the stroma vascular fraction, suggesting that this drug reduces the M1 proinflammatory state in ATMs, as an initial effect, in turn reducing the circulating levels of TNF-alpha and IL-6, and initiating an improvement in insulin signaling and sensitivity. | 19696185 |